Symmetrical inhibitor

The structure of urease from BPU was solved also with p-mercaptoethanol bound at the active site (134), where the inhibitor symmetrically bridges the two nickel ions through its sulfur atom (J(Ni Ni) = 3.1 A) and chelates one nickel through the terminal OH functionality, akin to the mode of inhibition by AHA. Because of the bridging thiolate, the two nickel ions are strongly antiferromagnet-ically coupled (23). No synthetic model for the p-mercaptoethanol-inhibited active site was reported yet. 

Hanessian and Devasthale, 1996] Hanessian, S., and Devasthale, P. Design and synthesis of novel, pseudo C2 symmetric inhibitors of HIV protease. Bioorg. Med. Chem. Lett. 6 (1996) 2201-2206... 

J ,3J ,4J ,5J )-2,5-bis(benzyloxy)-3,4-dihydroxy-Nd -bis (lS)-2-methyl-l-[(methylamino)carbonyl]propyl hexanediamide is a C2-symmetric HIV-1 protease inhibitor [29]. Derivatization in the para positions of the benzyl-oxy groups via microwave-assisted Stille reaction on the corresponding di-brominated inhibitor smoothly yielded the desired heteroarylated derivatives (Scheme 10). Interestingly, the 1,3-thiazole derivative showed a higher antiviral activity on the wild type virus than the lead compound. The activity remained at the same level in the presence of seriun. Unfortimately, a low activity was observed on mutants. 

Other types of HIV-1 protease inhibitors have also been prepared using microwave-promoted Suzuki reaction [37]. The symmetric cyclic sulfamide (3K,4S,5S,6it)-3,6-bis(phenoxymethyl)-2,7-bis[4-(2-thienyl)benzyl]-l,2,7-thi-adiazepane-4,5-diol 1,1-dioxide, for instance, was synthesized via cross-couphng of (3aS,4R,8it,8aS) - 5,7 - bis(4 - bromobenzyl) - 2,2 - dimethyl - 4,8 - bis-(phenoxymethyl) hexahydro [1,3] dioxolo [4,5 - d] [ 1,2,7 ] - thiadiazepine 6,6 - dioxide with 2-thienylboronic acid for 3 min at 45 W (Scheme 19). 

As a direct appUcation a potent C2-symmetric HIV-1 protease inhibitor (with two tetrazoles as carboxyl group bioisosteres) was prepared in one pot [77]. The process involved microwave-promoted cyanation followed by conversion of the nitrile group in a tetrazole with azide (Scheme 64). It is notable that the fimctionahzation was achieved so smoothly without side reactions such as the ehmination of water. 

Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor com-plexed to HlV-1 protease. Science 1990 249 527-33. 

A series of potent, linear C2-symmetric HIV-1 protease inhibitors with K, values in the nanomolar range was prepared from a diaryl bromide precursor emanating from a carbohydrate scaffold, by application of Heck, Suzuki, Stille, and cyanation reactions. Included in this series was the first reported microwave-promoted Suzuki coupling with an alkyl borane [41]. A very high-yielding Suzuki coupling is presented... 

Stereoselective synthesis of pseudo C2-symmetrical 1,3-dibenzyldiamino alcohol (S,S) (323) a core unit of HIV protease inhibitors, and the two meso-stereoisomers (323a) and (323b) was achieved by stereocontrolled addition of benzylmagnesium chloride to nitrones (63a) and (63b) (Scheme 2.137). The yield of (S,S)-(323), based on N-Boc-L-phenylalaninal, accounts for 23% (Scheme 2.137) (211). 

In a previous work, using D-fructose pyran- and furan- forms as inhibitors of D-fructose transport in CHO (Chinese Hamsters Ovary)-GLUT5 cells, Rollin, Holman and co-workers established that both ring forms were tolerated. The approach used was to block each hydroxyl function with allylic ether it was concluded that two sites, 0-2 (pyranose and furanose) and 0-6 (furanose) could be modified and addressed a visualization of vital interactions with the protein. These interactions were considered to occur because the D-fructofuranose form is relatively symmetrical for that reason, the binding site can arise either in anomeric center side or on the other side of the molecule. Hence D-fructopyranose appears to present to GLUT5 transporter by hydroxyl 3, 4, 5 recognition (Fig. 3). 

Selected entries from Methods in Enzymology [vol, page(s)] Acetylthiocholine as substrate, 251, 101-102 assay by ESR, 251, 102-105 inhibitors, 251, 103 modification by symmetrical disulfide radical, 251, 100 thioester substrate, 248, 16 transition state and multisubstrate analogues, 249, 305 enzyme receptor, similarity to collagen, 245, 3. 

Additional cycles of SBDD were imdertaken. They focused on separately optimizing each of the two halves of the symmetric diacylaminomethyl ketone inhibitor (Desjarlais et al., 1998 Thompson et al.. 

Figure 17.3 Schematic representation of the design of the symmetric cathepsin K inhibitor diacylaminomethyl ketone (1,3-bis[[A/-[(phenylmethoxy)carbonyl]-L-leucyl]amino]-2-propanone), based on the crystal structures of papain bound to leupeptin (Leu-Leu-Arg-aldehyde) and to Cbz-Leu-Leu-Leu-aldehyde, and an example of its further optimization.

A third dataset was built in order to demonstrate that the descriptor is relevant for estimating binding affinity in a QSAR analysis. This last dataset contains 49 HIV-1 protease inhibitors, the 3D coordinates of which were those used by Pastor et al. (30). It has the four transition-state isosteres—hydroxy ethylene, hydroxyethylamine, statine, and a symmetrical diol. The X-ray structures of molecules numbered 1 and 3-34 have been reported (31), whereas molecules numbered 35-50 were modeled on the crystallographic structure of the complex of HIV-1 protease with L-689,502 solved at 2.25 A resolution (32). The binding affinity is expressed as pIC50 values. 

They reasoned that if HIV PR incorporates symmetry into its active site structure, compounds that mimic this symmetry might be novel, more specific, and potent inhibitors and, furthermore, due to the bidirectionality of peptide bonds, might be sufficiently less peptidic in character and pharmacologically superior to the classical peptide-based compounds. The crystal structure of one of the first compounds from this series (A74704) verified the assumption of symmetrical binding conformation in the... 

---